Parental Knowledge About Respiratory Syncytial Virus (RSV) and Attitudes to Infant Immunization with Monoclonal Antibodies

• 2022

  Log in to bookmark this resource.

  Log in
• Gitte Mortensen; Kelly Harrod-Lui
PMID: 35929971DOI: https://dx.doi.org/10.1080/14760584.2022.2108799

---

Access Resources

• Journal ArticleEN
• Ask aRCie About This Resource

About

This article describes a study on parents' knowledge of respiratory syncytial virus (RSV) and their views on using monoclonal antibodies to protect infants. Most children get RSV by age two, causing many hospital visits. The study surveyed parents in eight countries and found that only 35% knew much about RSV. Parents were more likely to accept the new immunization if recommended by doctors and included in health programs. It highlights the need for better information about RSV before childbirth so parents can make informed decisions about protecting their babies during the first RSV season.

---

Tags

Focus Area: Infectious Disease

Audience: Physicians

Emergency Management Stage: Preparedness (Prevention / Protection)

Bundles: Nirsevimab Library

Keywords: Antibodies, Monoclonal; Attitude; Child; Child, Preschool; Immunization; Infant; Infant, Newborn; Health Knowledge, Attitudes, Practice; Parents; Respiratory Syncytial Virus Infections; Respiratory Syncytial Viruses; Vaccination; Immunization Programs; Respiratory Syncytial Virus, Human; Antineoplastic Agents, Immunological

Institutions: Sanofi; AnthroConsult

---

More like this

Cost of Respiratory Syncytial Virus Infections in US Infants: Systematic Literature Review and Analysis 2022 · Brandeis University, Sanofi Nirsevimab for Prevention of Hospitalizations Due to RSV in Infants 2023 · St. George's University Hospitals NHS Foundation Trust, University Hospital Southampton NHS Foundation Trust, Liverpool University Hospitals Foundation NHS Trust, Sanofi, Université Paris-Saclay, Assistance Publique - Hôpitaux de Paris (AP-HP) Expected Impact of Universal Immunization With Nirsevimab Against RSV-Related Outcomes and Costs Among All US Infants in Their First RSV Season: A Static Model 2022 · Sanofi, Evidera

---

The information provided on this website is for educational purposes only. It does not substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition.

---